Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy

BACKGROUND: Infliximab is an effective therapy for inflammatory bowel disease (IBD). However, more than 50% of patients lose response. Empiric dose intensification is not effective for all patients because not all patients have objective disease activity or subtherapeutic drug level. The aim was to...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Inflamm Bowel Dis
Egile Nagusiak: Huang, Vivian W., Prosser, Connie, Kroeker, Karen I., Wang, Haili, Shalapay, Carol, Dhami, Neil, Fedorak, Darryl K., Halloran, Brendan, Dieleman, Levinus A., Goodman, Karen J., Fedorak, Richard N.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Lippincott Williams & Wilkins 2015
Gaiak:
Original Clinical Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4450916/
https://ncbi.nlm.nih.gov/pubmed/25989340
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MIB.0000000000000376
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak